Drug intelligence / Profile preview

Unositol

Development stage: Unknown
Lead developer: Amdis Healthsciences
Modality: Small Molecules
Administration: Oral

Overview

**Unositol** is an orally administered, film-coated multinutrient nutraceutical tablet marketed by Amdis Healthsciences for polycystic ovary syndrome. Each tablet contains d-chiro-inositol 250 mg, alpha-lipoic acid 250 mg, folic acid 100 mcg, chromium picolinate 200 mcg, vitamin D3 200 IU, and manganese 10 mg. Amdis markets the product for support of ovulation, menstrual-cycle regularity, metabolic parameters, and PCOS-associated symptoms; it is a marketed consumer-health product rather than a clinical-stage single-molecule drug candidate. ([amdis.in](https://amdis.in/unositol-details.php))

Brand names: Unositol

Beyond the preview

Go deeper on Unositol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Unositol.

Explore the full profile